Middle East and Africa Psoriasis Drugs Market Report

Middle East and Africa Psoriasis Drugs Market Size

The Middle East & Africa Psoriasis Drugs Market size was valued at USD 0.60 billion in 2025 and is anticipated to reach USD 0.64 billion in 2026 from USD 1.12 billion by 2034, growing at a CAGR of 7.24% during the forecast period from 2026 to 2034.

The prevalence of psoriasis in this region is significant due to genetic predispositions and environmental triggers such as extreme heat and humidity. According to the International Federation of Psoriasis Associations, approximately 2% to 3% of the global population suffers from psoriasis, with varying incidence rates across different ethnic groups in the Middle East and Africa. According to the World Health Organization, psoriasis is a serious noncommunicable disease that imposes a substantial burden on healthcare systems and patients' quality of life. These statistics underscore the critical need for effective pharmacological solutions in regions where healthcare infrastructure is still developing. The market dynamics are influenced by the increasing awareness of advanced treatment options and the gradual improvement in diagnostic capabilities across major urban centers in countries like Saudi Arabia, South Africa, and the United Arab Emirates.

MARKET DRIVERS

Rising Prevalence of Chronic Inflammatory Conditions Drives Demand

The escalating incidence of psoriasis and related inflammatory disorders is propelling the Middle East and Africa psoriasis drugs market growth. Genetic factors combined with lifestyle changes have led to a noticeable increase in diagnosed cases, particularly in urban populations undergoing rapid modernization. According to the Journal of the American Academy of Dermatology, psoriasis affects approximately 1% to 8% of the population in various Middle Eastern countries, with higher rates observed in certain genetic clusters. This high prevalence rate creates a sustained patient pool requiring long-term management strategies, thereby driving consistent consumption of both traditional and novel therapies. Furthermore, as per the African Skin Disease Consortium, inflammatory skin conditions account for a significant proportion of dermatological consultations in sub-Saharan Africa, highlighting the widespread nature of the issue. As healthcare providers become more adept at diagnosing psoriasis accurately, the number of identified patients continues to rise, expanding the addressable market for drug manufacturers. The correlation between increased diagnosis rates and drug uptake is evident as patients seek relief from debilitating symptoms such as itching, pain, and visible plaques. This growing patient base necessitates a robust supply chain for effective medications, encouraging pharmaceutical companies to prioritize distribution networks in these regions. The demographic shift towards younger populations in many African nations also suggests a future increase in early-onset cases, further solidifying the demand trajectory for psoriasis drugs in the coming decade.

Improved Healthcare Infrastructure and Access to Biologics

Enhanced healthcare infrastructure and greater accessibility to advanced biologic therapies are pivotal in fuelling the Middle East and Africa psoriasis drugs market growth forward. Governments in Gulf Cooperation Council countries have significantly invested in modernizing medical facilities and integrating specialized dermatological care into public health systems. According to the Saudi Ministry of Health, the kingdom has expanded its network of specialized hospitals and clinics, improving access to advanced treatments for chronic diseases including psoriasis. This infrastructural development enables the administration of complex biologic agents that require careful monitoring and professional oversight, which were previously unavailable in many parts of the region. Additionally, the South African Medical Research Council highlights that increased funding for noncommunicable disease programs has facilitated better availability of essential medicines, including newer-generation psoriasis treatments. As insurance coverage expands and out-of-pocket expenses decrease for certain classes of drugs, patient adherence to treatment regimens improves substantially. The introduction of biosimilars has also played a crucial role by offering cost-effective alternatives to originator biologics, making them accessible to a broader segment of the population. These advancements reduce the financial barrier to entry for high-efficacy treatments, thereby increasing market penetration. The synergy between improved medical facilities and affordable drug options creates a conducive environment for market growth, ensuring that patients receive timely and effective care while sustaining commercial viability for pharmaceutical stakeholders.

MARKET RESTRAINTS

High Cost of Advanced Therapeutic Agents Restrains Growth

The prohibitive cost of advanced biologic and small molecule therapies significantly hampers the expansion of the Middle East and Africa psoriasis drugs market. While these treatments offer superior efficacy compared to traditional topicals, their high price points remain inaccessible to a large portion of the population lacking comprehensive insurance coverage. According to the World Bank, out-of-pocket health expenditure in many low- and middle-income countries in Africa exceeds 40% of total health spending, placing a severe financial burden on patients seeking chronic care. This economic reality forces many individuals to rely on less effective generic topicals or discontinue treatment altogether, limiting the adoption of premium psoriasis drugs. Furthermore, the International Society for Pharmacoeconomics and Outcomes Research notes that the annual cost of biologic therapy can exceed several thousand dollars, a sum that is unattainable for the average household in most African nations. Even in wealthier Middle Eastern countries, reimbursement policies may not fully cover newer agents, leading to restricted formulary access. The disparity between the clinical benefits of these drugs and their affordability creates a significant market restraint. Pharmaceutical companies face challenges in pricing strategies that balance profitability with accessibility, often resulting in limited market penetration for high-end products. This financial barrier prevents the full realization of the market potential, as a substantial number of eligible patients remain untreated or undertreated due to cost constraints, thereby stifling overall market growth despite rising disease prevalence.

Limited Regulatory Harmonization and Approval Delays

Fragmented regulatory frameworks and prolonged approval processes for new drugs further impedes the regional market expansion. Unlike unified markets such as the European Union, this region comprises numerous countries with distinct regulatory bodies, each requiring separate submissions and evaluations for drug registration. According to the World Health Organization, regulatory capacity varies widely across African nations, with many lacking the resources to conduct efficient reviews of complex biologic applications, leading to delays of several years. This fragmentation increases the operational burden for pharmaceutical companies, which must navigate diverse legal and administrative landscapes to bring products to market. In the Middle East, while some countries have streamlined processes, others still adhere to lengthy evaluation timelines that postpone patient access to innovative therapies. The African Medicines Agency aims to harmonize regulations, but its full implementation remains ongoing, meaning current disparities persist. These delays prevent patients from benefiting from the latest scientific advancements in psoriasis care, creating a gap between global innovation and local availability. The uncertainty surrounding approval timelines discourages some manufacturers from prioritizing smaller markets within the region, limiting the diversity of available treatment options. Consequently, the market suffers from a slower adoption curve for new entrants, restricting competition and keeping prices elevated due to limited supply of advanced molecules. This regulatory inertia fundamentally constrains market dynamism and patient choice.

MARKET OPPORTUNITIES

Expansion of Telemedicine and Digital Health Platforms

The rapid adoption of telemedicine and digital health platforms is a substantial opportunity for enhancing patient engagement and drug adherence in the Middle East and Africa Psoriasis Drugs Market. Digital solutions enable remote monitoring of skin conditions, facilitating timely adjustments to treatment plans without the need for frequent physical visits to specialized clinics. According to the Global System for Mobile Communications Association, mobile phone penetration in sub-Saharan Africa has surpassed 50%, providing a robust infrastructure for digital health interventions. This widespread connectivity allows healthcare providers to reach patients in rural and underserved areas, bridging the gap in access to dermatological expertise. Teleconsultation can lead to earlier diagnosis and initiation of appropriate therapy, thereby expanding the patient base for psoriasis drugs. Furthermore, digital apps that track symptom progression and medication schedules improve adherence rates, which is critical for the effectiveness of chronic disease management. The Dubai Health Authority highlights that the integration of artificial intelligence in diagnostic tools has improved the accuracy of remote skin assessments, fostering greater confidence in telehealth services. As these technologies mature, they create new channels for pharmaceutical companies to educate patients and support prescribers, driving demand for prescribed medications. The convenience and accessibility offered by digital platforms reduce the friction associated with traditional healthcare delivery, making it easier for patients to maintain continuous treatment. This technological evolution opens avenues for innovative marketing and patient support programs, ultimately stimulating market growth through improved care continuity.

Growing Local Manufacturing and Biosimilar Production

The emergence of local manufacturing capabilities and the production of biosimilars offer a promising avenue for reducing costs and increasing the availability of psoriasis treatments in the Middle East and Africa. Several countries in the region are investing in pharmaceutical industrial zones to decrease reliance on imports and enhance self-sufficiency in essential medicines. According to the Gulf Cooperation Council Standardization Organization, local production of generic and biosimilar drugs has increased by 15% in recent years, driven by government incentives and strategic partnerships with international firms. This shift towards domestic manufacturing lowers logistics costs and mitigates supply chain disruptions, ensuring a more stable availability of psoriasis drugs. Biosimilars, which are highly similar to approved biologic reference products, provide a cost-effective alternative that can significantly expand access to advanced therapies. The Egyptian Ministry of Health emphasizes that local production of complex biologics is a strategic priority to address the high burden of chronic diseases. By producing these drugs locally, countries can negotiate better pricing and improve reimbursement coverage, making treatments more affordable for the general population. This trend also attracts foreign direct investment in the pharmaceutical sector, fostering technology transfer and skill development. The resulting increase in competitive pressure among suppliers drives down prices and encourages innovation, benefiting both payers and patients. As local capacity grows, the market will see a broader range of affordable options, stimulating volume growth and enhancing overall market resilience.

MARKET CHALLENGES

Inadequate Dermatologist Workforce and Specialist Shortage

The scarcity of qualified dermatologists and specialized healthcare professionals poses a significant challenge to the effective management of psoriasis and the growth of the Middle East and Africa Psoriasis Drugs Market. Many countries in the region suffer from a severe imbalance in the doctor-to-patient ratio, particularly in rural areas where access to specialist care is virtually nonexistent. According to the World Health Organization, the density of health workers in Africa remains below the threshold required to meet basic health needs, with dermatology being one of the most underrepresented specialties. This shortage leads to delayed diagnoses and inappropriate initial treatments, as primary care providers may lack the expertise to identify psoriasis accurately or prescribe advanced therapies. Without proper specialist guidance, patients are less likely to receive optimal care, resulting in poor disease control and reduced demand for sophisticated drugs. The Saudi Arabian Board of Dermatology highlights that despite efforts to train more specialists, the demand far outstrips the supply, creating long waiting times for appointments. This bottleneck restricts the flow of patients into the specialized treatment pipeline, limiting the prescription of high-value biologics and systemic agents. The lack of expert oversight also contributes to lower adherence rates, as patients may not receive adequate education on disease management. Addressing this workforce gap requires substantial investment in medical education and training programs, which is a long-term endeavor. Until then, the market remains constrained by the limited capacity of the healthcare system to diagnose and treat complex cases effectively.

Low Disease Awareness and Social Stigma

Persistent low levels of public awareness regarding psoriasis and the associated social stigma significantly hinder market expansion by preventing patients from seeking timely medical intervention. Many individuals in the Middle East and Africa mistakenly view psoriasis as a contagious condition or a minor cosmetic issue, leading to hesitation in consulting healthcare providers. According to the International Psoriasis Council, stigma affects over 60% of psoriasis patients globally, causing psychological distress and social isolation, which is particularly pronounced in communities with limited health literacy. This misconception delays diagnosis and treatment initiation, allowing the disease to progress to more severe stages that are harder to manage. Cultural beliefs and traditional remedies often take precedence over evidence-based medicine, further diverting patients from effective pharmaceutical solutions. According to the African Union Commission on Social Affairs, health education campaigns focused on skin diseases are insufficient, leaving large segments of the population uninformed about the chronic nature of psoriasis. Without adequate awareness, patients do not recognize the need for continuous treatment, resulting in intermittent therapy and poor outcomes. This lack of understanding reduces the perceived value of prescription drugs, limiting market demand. Overcoming this barrier requires sustained public health initiatives to educate communities and dispel myths, but such efforts are often underfunded. Until awareness improves, a significant portion of the affected population will remain outside the formal healthcare system, constraining the overall market potential for psoriasis drugs.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Drug Type Insights

The pharmaceuticals segment dominated the market by holding the largest share of the Middle East and Africa psoriasis drugs market in 2025. The dominance of pharmaceuticals segment in the regional market is majorly driven by its widespread availability and established clinical protocols and well-established clinical guidelines that recommend topical and oral agents as first-line treatments for mild to moderate psoriasis. According to the American Academy of Dermatology, topical therapies remain the cornerstone of treatment for over 80% of patients with limited disease extent, ensuring high prescription volumes in primary care settings. This widespread recommendation ensures a steady demand for conventional drugs across both public and private healthcare facilities in the Middle East and Africa. Furthermore, the World Health Organization highlights that essential medicines lists in many African countries prioritize affordable generic formulations, which fall under the pharmaceuticals category. This policy framework supports the continued use of cost-effective treatments over expensive biologics, particularly in resource-constrained settings. The lower production costs associated with small molecule drugs allow manufacturers to maintain competitive pricing, making viable options for out-of-pocket payers. As a result, the volume of pharmaceutical prescriptions significantly outweighs that of biopharmaceuticals, sustaining the segment's market leadership. The familiarity of healthcare providers with these agents also reduces hesitation in prescribing, further cementing their position as the preferred initial therapy for the majority of diagnosed cases in the region.

However, the biopharmaceuticals segment is projected to register the highest CAGR of 10.3% during the forecast period in this regional market owing to the increasing adoption of targeted biologics and biosimilars and the entry of biosimilars that offer similar clinical benefits to originator biologics at a significantly lower cost. According to the European Medicines Agency, biosimilars can reduce treatment costs by 30% to 50%, making advanced therapies more accessible to patients in emerging markets. This price reduction is critical in the Middle East and Africa, where high out-of-pocket expenses previously limited the uptake of premium biologics. As patents expire for major blockbuster drugs, local and international manufacturers are launching biosimilar versions, intensifying competition and driving down prices. The Saudi Food and Drug Authority has approved several biosimilars for psoriasis treatment, reflecting a regulatory environment that encourages market entry of affordable alternatives. This increased availability expands the patient pool eligible for biologic therapy, particularly among those who failed conventional treatments but could not afford original brands. The cost-effectiveness of biosimilars also appeals to insurance providers and government health schemes, leading to broader formulary inclusion. Consequently, the volume of biologic prescriptions is rising steadily, propelling the segment's growth trajectory. The shift towards value-based healthcare further supports this trend, as payers seek efficient solutions that balance clinical outcomes with financial sustainability.

By Route of Administration Insights

The topical segment captured 65.6% of the regional market share in 2025. The growth of the topical segment in the Middle East and Africa psoriasis drugs market can be driven by global and regional clinical guidelines that designate topical agents as the first-line therapy for mild to moderate psoriasis. According to the British Association of Dermatologists, topical treatments are effective for up to 80% of patients who present with limited body surface area involvement, which constitutes the majority of the diagnosed population. This widespread clinical endorsement ensures that primary care physicians and general practitioners frequently prescribe topical formulations as the initial intervention. In the Middle East and Africa, where access to specialized dermatological care may be limited in rural areas, topicals provide a manageable and safe option for general practitioners to administer. The ease of use and minimal systemic side effects make them suitable for long-term maintenance therapy, reducing the risk of adverse events associated with oral or injectable drugs. As per the African Journal of Medicine and Health Sciences, topical steroids remain the most commonly prescribed medication for inflammatory skin conditions in primary healthcare settings across the continent. This high prescription volume sustains the segment's market leadership. Furthermore, the availability of various formulations allows for customization based on lesion location and patient preference, enhancing compliance. The low barrier to entry for topical treatments ensures they remain the backbone of psoriasis management strategies in the region.

On the other end, the intravenous segment within systemic administration is expected to grow at the fastest CAGR of 9.5% over the forecast period due to the increasing use of infusion-based biologics for severe and resistant cases and the necessity to manage severe and refractory psoriasis cases that do not respond to topical or oral therapies. According to the National Psoriasis Foundation, approximately 20% to 30% of psoriasis patients develop moderate to severe disease requiring systemic intervention, with a subset needing infusion-based biologics for optimal control. As diagnostic capabilities improve in countries like Saudi Arabia and South Africa, more patients are being identified with severe disease phenotypes, increasing the demand for potent intravenous treatments. These therapies offer rapid and profound symptom relief, which is critical for patients experiencing significant quality of life impairment. The establishment of dedicated infusion centers in major hospitals facilitates the safe administration of these complex drugs, addressing previous logistical barriers. The Dubai Health Authority reports an increase in the number of certified infusion facilities, reflecting the growing infrastructure support for advanced therapies. This expanded capacity allows more patients to access intravenous treatments, driving segment growth. Additionally, the predictable pharmacokinetics of intravenous biologics provide clinicians with greater confidence in dosing and efficacy, encouraging their use in complex cases. As healthcare systems prioritize effective management of severe chronic diseases, the utilization of intravenous agents is set to rise substantially.

COUNTRY ANALYSIS

Saudi Arabia Psoriasis Drugs Market Analysis

Saudi Arabia dominated the market by accounting for the leading share of the Middle East and Africa psoriasis drugs market in 2025 and is likely to see steady expansion over the next few years due to robust government healthcare initiatives, a high prevalence of autoimmune disorders. The Kingdom’s Vision 2030 healthcare transformation program has significantly increased investment in specialized medical services, including dermatology. According to the Saudi Ministry of Health, the number of specialized dermatology clinics has increased by 25% in recent years, enhancing access to advanced psoriasis treatments. This infrastructural expansion supports the adoption of biologic therapies and improves diagnostic accuracy. The high disposable income in urban areas like Riyadh and Jeddah enables patients to afford premium medications, driving market value. Additionally, the Saudi Food and Drug Authority has streamlined approval processes for new biologics, reducing time to market for innovative drugs. The prevalence of psoriasis in the Kingdom is estimated to be around 2.5%, creating a substantial patient base. The government’s emphasis on noncommunicable disease management ensures consistent funding for chronic care programs. Local manufacturing initiatives are also gaining traction, aiming to produce biosimilars to reduce costs. These factors combine to make Saudi Arabia a key growth engine for the regional market, with strong demand for both traditional and advanced therapies.

United Arab Emirates Psoriasis Drugs Market Analysis

The United Arab Emirates serves as a hub for advanced medical tourism and healthcare innovation in the region, influencing the adoption of cutting-edge psoriasis treatments. The country boasts one of the highest healthcare spending per capita in the Middle East, facilitating access to the latest biologic agents. The Dubai Health Authority states that the emirate has integrated artificial intelligence into diagnostic workflows, improving early detection and personalized treatment plans for psoriasis patients. This technological edge attracts patients from neighboring countries seeking specialized care. The prevalence of psoriasis in the UAE is comparable to global averages, but the severity often prompts earlier intervention with systemic therapies. The government’s mandatory health insurance scheme in Dubai and Abu Dhabi ensures broad coverage for essential and specialized medications, including biologics. The presence of international pharmaceutical headquarters in Dubai facilitates faster launch of new products. The cultural emphasis on appearance and quality of life drives high demand for effective skin clearance treatments. The UAE’s strategic location and advanced logistics infrastructure also support efficient distribution of temperature-sensitive drugs. These elements position the UAE as a leader in market sophistication and adoption rates for novel psoriasis therapies.

Israel Psoriasis Drugs Market Analysis

Israel maintains a leading role in the Middle East Psoriasis Drugs Market due to its advanced research capabilities and high standard of healthcare delivery. The country is a global center for dermatological research, contributing significantly to the development of new psoriasis treatments. According to the Israeli Ministry of Health, nearly all citizens have access to comprehensive health coverage, which includes advanced biologic therapies for severe psoriasis. This universal access ensures high penetration rates for new drugs upon approval. The prevalence of psoriasis in Israel is slightly higher than the global average, attributed to genetic factors in the Jewish population. The strong collaboration between academic institutions and pharmaceutical companies accelerates the translation of research into clinical practice. Patients in Israel benefit from early access to clinical trials and innovative therapies before they reach other regional markets. The high health literacy rate among the population drives informed demand for effective treatments. The centralized healthcare system allows for efficient data collection and outcome monitoring, supporting evidence-based prescribing. These factors create a dynamic and mature market environment characterized by rapid adoption of scientific advancements and high patient engagement in treatment decisions.

COMPETITIVE LANDSCAPE

The competition in the Middle East and Africa Psoriasis Drugs Market is characterized by the presence of both multinational pharmaceutical giants and emerging local manufacturers. Multinational companies dominate the segment for advanced biologic therapies due to their extensive research capabilities and established brand reputation. They compete primarily on clinical efficacy, safety profiles, and innovative delivery mechanisms. Local manufacturers focus on producing cost effective generic topicals and oral systemic agents, catering to the price sensitive segments of the population. The entry of biosimilars has intensified competition by offering affordable alternatives to originator biologics, thereby pressuring prices and expanding access. Competitive dynamics are further influenced by regulatory environments, where faster approval processes in certain countries attract early product launches. Companies differentiate themselves through robust patient support programs, digital health integration, and strategic collaborations with healthcare institutions. The race to secure formulary inclusion in public and private insurance schemes is a key competitive battleground. As awareness grows and healthcare infrastructure improves, the competitive landscape is shifting towards value based offerings that balance clinical outcomes with affordability. This evolution encourages continuous innovation and strategic agility among market participants to maintain relevance and growth.

KEY MARKET PLAYERS

Companies playing an active role in the MEA Psoriasis Drugs Market include

• Johnson & Johnson (USA)
• Novartis International AG (Switzerland)
• Pfizer Inc. (USA)
• Merck & Co., Inc. (USA)
• Celgene Corporation (USA)
• Janssen Biotech, Inc. (USA)
• Stiefel Laboratories, Inc. (USA)
• Takeda Pharmaceutical Company Limited (Japan)
• Amgen (USA)
• AbbVie (USA)

Top Players in the Market

Novo Nordisk A/S

Novo Nordisk A/S maintains a strong presence in the Middle East and Africa Psoriasis Drugs Market through its innovative biologic therapies targeting specific immune pathways. The company focuses on delivering high efficacy treatments that improve patient quality of life significantly. Recent initiatives include expanding distribution networks in key Gulf countries to ensure broader access to their advanced medications. Novo Nordisk collaborates with local healthcare providers to enhance disease awareness and early diagnosis capabilities. Their commitment to research and development drives the introduction of novel molecules that address unmet medical needs in severe psoriasis cases. The company also engages in patient support programs that facilitate adherence to long term treatment regimens. By leveraging strategic partnerships with regional distributors, Novo Nordisk ensures consistent supply chain reliability. These efforts reinforce their reputation as a leader in dermatological care and strengthen their competitive position in the evolving market landscape.

AbbVie Inc

AbbVie Inc contributes significantly to the market by offering a robust portfolio of immunology focused biologics designed for moderate to severe psoriasis. The company emphasizes scientific innovation and clinical excellence to deliver superior therapeutic outcomes for patients. AbbVie has recently strengthened its market position by launching educational campaigns aimed at healthcare professionals in South Africa and Saudi Arabia. These initiatives promote best practices in managing complex psoriasis cases using their targeted therapies. The company also invests in local manufacturing collaborations to improve affordability and accessibility of its products. AbbVie actively participates in regional medical conferences to share latest clinical data and real world evidence. Their focus on patient centric solutions includes digital tools that support disease monitoring and management. These strategic actions enhance brand loyalty and drive sustained growth in the Middle East and Africa region.

Sanofi S.A

Sanofi S.A plays a pivotal role in the market by providing advanced biologic treatments that target interleukin pathways for effective psoriasis management. The company is dedicated to transforming care for chronic inflammatory diseases through continuous innovation and patient support. Sanofi has recently expanded its footprint in the United Arab Emirates by establishing specialized training centers for dermatologists. These centers focus on optimizing the use of their flagship biologic agents in clinical practice. The company also partners with local governments to integrate psoriasis care into national health strategies. Sanofi’s commitment to accessibility is evident in their tiered pricing models that cater to diverse economic segments. They actively engage in public health initiatives to reduce stigma and improve disease awareness. These comprehensive efforts solidify Sanofi’s position as a key contributor to the advancement of psoriasis treatment in the region.

Top Strategies Used by Key Market Participants

Key players in the Middle East and Africa Psoriasis Drugs Market employ several strategic approaches to strengthen their competitive standing and expand their reach. One primary strategy involves forming strategic partnerships with local distributors and healthcare providers to enhance supply chain efficiency and market penetration. These collaborations ensure that essential medications reach remote and underserved areas effectively. Another critical strategy is the localization of manufacturing facilities to produce biosimilars and generic alternatives. This approach reduces costs and makes advanced therapies more affordable for a broader patient population. Companies also invest heavily in medical education and awareness campaigns to train healthcare professionals on the latest treatment protocols. These initiatives improve diagnostic accuracy and appropriate prescribing practices. Additionally, firms leverage digital health platforms to engage patients and improve adherence to treatment regimens. Regulatory engagement is another vital strategy, where companies work closely with local authorities to streamline approval processes for new drugs. By aligning with national health priorities and investing in community based programs, market participants build trust and establish long term sustainability in the region.

MARKET SEGMENTATION

This research report on the Middle East and Africa psoriasis drugs market has been segmented and sub-segmented into the following categories

By Drug Type

• Pharmaceuticals
• Biopharmaceuticals

By Route of Administration

• Topical
• Systemic
  • Oral
  • Intravenous
  • Others

By Target

• Tumour Necrosis Factor (TNF)
• Phosphodiesterase Type 4 (PDE4)
• Interleukin

By Country

• KSA
• UAE
• Israel
• Rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• Rest of MEA